These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 15932344)

  • 1. Pharmacokinetics/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis.
    Cremers SC; Pillai G; Papapoulos SE
    Clin Pharmacokinet; 2005; 44(6):551-70. PubMed ID: 15932344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimizing the management of postmenopausal osteoporosis with bisphosphonates: the emerging role of intermittent therapy.
    Miller PD
    Clin Ther; 2005 Apr; 27(4):361-76. PubMed ID: 15922811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beyond daily dosing: clinical experience.
    Cooper C
    Bone; 2006 Apr; 38(4 Suppl 1):S13-7. PubMed ID: 16520105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug insight: Bisphosphonates for postmenopausal osteoporosis.
    Chapurlat RD; Delmas PD
    Nat Clin Pract Endocrinol Metab; 2006 Apr; 2(4):211-9; quiz following 238. PubMed ID: 16932286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of bisphosphonates in the prevention and treatment of osteoporosis.
    Papapoulos SE
    Am J Med; 1993 Nov; 95(5A):48S-52S. PubMed ID: 8256796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pharmacokinetic and pharmacodynamic model for intravenous bisphosphonate (pamidronate) in osteoporosis.
    Cremers S; Sparidans R; den HJ; Hamdy N; Vermeij P; Papapoulos S
    Eur J Clin Pharmacol; 2002 Feb; 57(12):883-90. PubMed ID: 11936708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term use of bisphosphonates in osteoporosis.
    Watts NB; Diab DL
    J Clin Endocrinol Metab; 2010 Apr; 95(4):1555-65. PubMed ID: 20173017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intermittent bisphosphonate therapy in postmenopausal osteoporosis: progress to date.
    Reginster JY; Malaise O; Neuprez A; Jouret VE; Close P
    Drugs Aging; 2007; 24(5):351-9. PubMed ID: 17503893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical evaluation of novel bisphosphonate dosing regimens in osteoporosis: the role of comparative studies and implications for future studies.
    Cosman F; Borges JL; Curiel MD
    Clin Ther; 2007 Jun; 29(6):1116-27. PubMed ID: 17692726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bisphosphonates for prevention of postmenopausal osteoporosis.
    Ravn P
    Dan Med Bull; 2002 Feb; 49(1):1-18. PubMed ID: 11894721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pharmacokinetics of bisphosphonate.].
    Nakamura M; Koide M; Udagawa N
    Clin Calcium; 2016; 26(11):1561-1570. PubMed ID: 27777389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bisphosphonates: preclinical aspects and use in osteoporosis.
    Fleisch HA
    Ann Med; 1997 Feb; 29(1):55-62. PubMed ID: 9073324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term safety of bisphosphonate therapy for osteoporosis: a review of the evidence.
    Liberman UA
    Drugs Aging; 2006; 23(4):289-98. PubMed ID: 16732688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of bisphosphonates on fracture incidence and bone metabolism in rheumatoid arthritis patients in general practice taking long-term corticosteroid therapy: a retrospective study.
    Katayama K; Matsuno T
    Clin Drug Investig; 2008; 28(3):149-58. PubMed ID: 18266400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing.
    Bauss F; Russell RG
    Osteoporos Int; 2004 Jun; 15(6):423-33. PubMed ID: 15205712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bisphosphonates, specific inhibitors of osteoclast function and a class of drugs for osteoporosis therapy.
    Li B; Ling Chau JF; Wang X; Leong WF
    J Cell Biochem; 2011 May; 112(5):1229-42. PubMed ID: 21465521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term outcome of weekly bisphosphonates.
    Rizzoli R
    Clin Orthop Relat Res; 2006 Feb; 443():61-5. PubMed ID: 16462427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ibandronate treatment for osteoporosis: rationale, preclinical, and clinical development of extended dosing regimens.
    Epstein S
    Curr Osteoporos Rep; 2006 Mar; 4(1):14-20. PubMed ID: 16527003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150 mg and risedronate 150 mg.
    Epstein S; Jeglitsch M; McCloskey E
    Curr Med Res Opin; 2009 Dec; 25(12):2951-60. PubMed ID: 19835464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. On the pharmacological evaluation of bisphosphonates in humans.
    Cremers S; Ebetino FH; Phipps R
    Bone; 2020 Oct; 139():115501. PubMed ID: 32599224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.